AqVida to debut oncology generics at CPhI Barcelona
Press Release | AqVida GmbH
SEPTEMBER 15, 2016
Hamburg, Germany: – Innovative German oncology generics specialist AqVida will use Europe’s largest pharma trade show, CPhI Worldwide, to introduce its New Generic Generation of oncology drugs, including Imatinib and Sunitinib. The new generics target patents expire in end of 2016 and 2021, respectively.
AqVida is one of the first generic companies to finalize development of a generic version of Sutent® [Sunitinib]. Being produced in a patent-free country, AqVida’s Sunitinib can be offered and commercialized into territories where no patent applies. AqVida has developed all four strength variants using back-integrated API.
The Hamburg-based oncology manufacturer, which is dedicated to development, registration, manufacturing and licensing/distribution of oncology generics, will be an exhibitor at CPHI 2016 in Barcelona, with its own stand (Booth 7C60, Hall 7) at Fira de Barcelona.
Further highlights of the AqVida display will be presentation of new drugs in its development pipeline as well as its recently completed innovative robotic production line in Germany.
The new “Zero Loss” facility features unique engineering technology to manufacture parenteral oncology generics and antibody drug conjugates (ADCs). This facility represents a major step forward for the pharma industry, using totally robotic controlled filling processes in an isolator for parenteral cytotoxics.
The AqVida team designed the ultra-modern facility specifically to guarantee flawless product quality, thus improving the patient safety. Aqvida is involved in the development of several concept designs, including marketing assistance to “Define Quality in Oncology”.
AqVida is an established presence at CPhI Worldwide, which is a centerpiece “must attend” event for pharmaceutical companies from all over the world. CPhI 2016 is expected to attract visitors and exhibitors from about 150 countries.
“Every year we enjoy exhibiting at CPHI and look forward to Barcelona,” said AqVida’s Commercial Director, Jürgen Lehmberg. “We are expecting CPhI 2016 to be our most successful showing yet,” he added.
“This year we will meet our partners from Europe, Latin America, Middle East and North Africa, South East Asia and Sub-Saharan African area for networking, finalizing negotiations and to build up long-term business relationships,” said Mr. Lehmberg.
“We will use CPhI to connect with licensing and distribution partners across Europe to expand our presence there and in other regulated markets, such as South East Asia, LatAm, Canada and Australia,” Mr. Lehmberg explained.
AqVida will also look to open negotiation with new license partners on co-development projects to realize synergies, bundling strengths and combined development forces for greater efficiencies and mutual benefit.
Higher quality supply
AqVida CEO and Founder Wolfgang Heinze added: “We have several opportunities available for out-licensing of our products, depending on client portfolio and market stance,”.
Mr. Heinze said he was particularly keen to talk to pharmaceutical companies looking to bring AqVida’s “Made in Germany” quality GMP certified oncology products to their markets. The company was actively seeking professional partners with identical company philosophy to register and distribute AqVida’s product family into its home markets.
“Our new production hi-tech facility is able to produce the world’s best medicines,” said Mr. Heinze, noting that a growing number of pharmaceutical companies especially in Asia, MENA/GCC, Africa and South America were looking for alternative higher quality supplies in generic oncologic drugs as regulatory requirements became ever more stringent, in Europe and beyond.
“AqVida is able to match these needs with EU quality products at a competitive price level and several other benefits, such as keeping inventory, short lead-time, dossier maintenance, etc.,” said Mr. Heinze.
“AqVida is a full service pharmaceutical company that is also very fast and flexible in finding optimum solutions for our clients,” Mr. Heinze concluded.
AqVida is a German oncology FDF manufacturer that is fully dedicated and specialized in the development, registration, manufacturing and distribution of finished dosage forms mainly for the oncology sector. It has developed a portfolio of medicines for treating the most common types of cancer.
AqVida’s expertise in generic oncology products has made the company a leading partner in the pharmaceutical industry.
AqVida works alongside some of the leading names in the oncology sector. In co-operation with its partners, AqVida has achieved substantial development and growth with its oncology portfolio.
AqVida is a pharmaceutical company with an impressive track record in fulfilling all client requirements from API sourcing through to EU market release for finished products. Teams of experts in development, regulatory affairs, patent issues and laboratory work bring skills and knowledge together to achieve optimum results for customers.
AqVida complies with all German and EU legal requirements for the pharmaceutical industry and is GMP certified by the German Health Authorities. As a European organization, AqVida has the knowledge and resources to provide regulatory support to meet the requirements of the complex and highly regulated EU market.
About CPhI Worldwide 2016
CPhI Worldwide is the flagship annual trade show for pharma ingredients and partner sourcing providing delegates and exhibitors opportunities to arrange face-to-face meetings with potential international pharmaceutical partners and collaborators, as well as gain insights on latest industry trends.
Now in its 27th year, the 2016 fair is a three-day event opening October 4 at the Fira de Barcelona exhibition center. Last year’s event in Madrid attracted some 36,000 delegates and 2,500 exhibitor companies from more than 150 countries worldwide.
The CPhl Worldwide show is being held alongside three other zoned exhibitions; ICSE Outsourcing solutions, P-MEC Machinery and Equipment and InnoPack pharmaceutical packaging events.
The Pre-Connect Conference on October 3 brings together senior stakeholders from all segments of the industry for a series of market-led educational modules on latest trends and topics while the CPhI Pharma Awards, presented on the first evening of the conference, honor innovative companies and leaders.
The CPhI series is staged by leading Global B2B Events Organizer and Publisher UBM Live More information at: http://www.cphi.com/europe/
Jürgen Lehmberg, Commercial Director, AqVida GmbH
Wolfgang Heinze, CEO, AqVida GmbH
Tel: +49 40 380 37190
Click on AqVida to debut oncology generics at CPhI Barcelona for other information.
Click on AqVida to contact the company directly.